Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism-Reference-Cited by-同舟云学术

Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism

Published:2005-05 Issue:5 Volume:59 Page:552-563
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Shon Ji-Hong,Yoon Young-Ran,Kim Min-Jung,Kim Kyoung-Ah,Lim Young-Chae,Liu Kwang-Hyeon,Shin Dong-Hoon,Lee Chung Han,Cha In-June,Shin Jae-Gook

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.2005.02364.x/fullpdf

Reference40 articles.

1. A study of the metabolic fate of chlorpropamide in man

2. Pharmacokinetics and biotransformation of chlorpropamide in man

3. Metabolism of Chlorpropamide

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenomics: The roles of genetic factors on treatment response and outcomes in diabetes;Internet of Things and Machine Learning for Type I and Type II Diabetes;2024

2. Construction of a fused grid-based CYP2C19-Template system and the application;Drug Metabolism and Pharmacokinetics;2023-02

3. Construction of a fused grid-based template system of CYP2C9 and its application;Drug Metabolism and Pharmacokinetics;2022-08

4. CYP2C19 Loss‐of‐function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes;Clinical Pharmacology & Therapeutics;2021-10-30

5. Altered tolbutamide pharmacokinetics by a decrease in hepatic expression of CYP2C6/11 in rats pretreated with 5-fluorouracil;Xenobiotica;2017-01-31